These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 28166537)

  • 1. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer.
    Zhao D; Lu X; Wang G; Lan Z; Liao W; Li J; Liang X; Chen JR; Shah S; Shang X; Tang M; Deng P; Dey P; Chakravarti D; Chen P; Spring DJ; Navone NM; Troncoso P; Zhang J; Wang YA; DePinho RA
    Nature; 2017 Feb; 542(7642):484-488. PubMed ID: 28166537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.
    Augello MA; Liu D; Deonarine LD; Robinson BD; Huang D; Stelloo S; Blattner M; Doane AS; Wong EWP; Chen Y; Rubin MA; Beltran H; Elemento O; Bergman AM; Zwart W; Sboner A; Dephoure N; Barbieri CE
    Cancer Cell; 2019 Apr; 35(4):603-617.e8. PubMed ID: 30930119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer.
    Zhao D; Cai L; Lu X; Liang X; Li J; Chen P; Ittmann M; Shang X; Jiang S; Li H; Meng C; Flores I; Song JH; Horner JW; Lan Z; Wu CJ; Li J; Chang Q; Chen KC; Wang G; Deng P; Spring DJ; Wang YA; DePinho RA
    Cancer Discov; 2020 Sep; 10(9):1374-1387. PubMed ID: 32385075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organ-specific regulation of CHD1 by acute PTEN and p53 loss in mice.
    Rahmy S; Cheng X; Wang M; Feng H; Qiu W; Zhao R; Lu X
    Biochem Biophys Res Commun; 2020 May; 525(3):614-619. PubMed ID: 32115152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
    Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
    Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
    Tang YC; Ho SC; Tan E; Ng AWT; McPherson JR; Goh GYL; Teh BT; Bard F; Rozen SG
    Breast Cancer Res; 2018 Mar; 20(1):22. PubMed ID: 29566768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.
    Kari V; Mansour WY; Raul SK; Baumgart SJ; Mund A; Grade M; Sirma H; Simon R; Will H; Dobbelstein M; Dikomey E; Johnsen SA
    EMBO Rep; 2016 Nov; 17(11):1609-1623. PubMed ID: 27596623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells.
    Kikuno N; Shiina H; Urakami S; Kawamoto K; Hirata H; Tanaka Y; Majid S; Igawa M; Dahiya R
    Int J Cancer; 2008 Aug; 123(3):552-60. PubMed ID: 18431742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer.
    Liu W; Lindberg J; Sui G; Luo J; Egevad L; Li T; Xie C; Wan M; Kim ST; Wang Z; Turner AR; Zhang Z; Feng J; Yan Y; Sun J; Bova GS; Ewing CM; Yan G; Gielzak M; Cramer SD; Vessella RL; Zheng SL; Grönberg H; Isaacs WB; Xu J
    Oncogene; 2012 Aug; 31(35):3939-48. PubMed ID: 22139082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.
    Burkhardt L; Fuchs S; Krohn A; Masser S; Mader M; Kluth M; Bachmann F; Huland H; Steuber T; Graefen M; Schlomm T; Minner S; Sauter G; Sirma H; Simon R
    Cancer Res; 2013 May; 73(9):2795-805. PubMed ID: 23492366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human CHD1 is required for early DNA-damage signaling and is uniquely regulated by its N terminus.
    Zhou J; Li J; Serafim RB; Ketchum S; Ferreira CG; Liu JC; Coe KA; Price BD; Yusufzai T
    Nucleic Acids Res; 2018 May; 46(8):3891-3905. PubMed ID: 29529298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.
    Chatterjee N; Pazarentzos E; Mayekar MK; Gui P; Allegakoen DV; Hrustanovic G; Olivas V; Lin L; Verschueren E; Johnson JR; Hofree M; Yan JJ; Newton BW; Dollen JV; Earnshaw CH; Flanagan J; Chan E; Asthana S; Ideker T; Wu W; Suzuki J; Barad BA; Kirichok Y; Fraser JS; Weiss WA; Krogan NJ; Tulpule A; Sabnis AJ; Bivona TG
    Cell Rep; 2019 Aug; 28(9):2317-2330.e8. PubMed ID: 31461649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
    Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
    Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer.
    Ding Y; Li N; Dong B; Guo W; Wei H; Chen Q; Yuan H; Han Y; Chang H; Kan S; Wang X; Pan Q; Wu P; Peng C; Qiu T; Li Q; Gao D; Xue W; Qin J
    J Clin Invest; 2019 Feb; 129(2):759-773. PubMed ID: 30496141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness.
    Huang S; Gulzar ZG; Salari K; Lapointe J; Brooks JD; Pollack JR
    Oncogene; 2012 Sep; 31(37):4164-70. PubMed ID: 22179824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual degradation signals destruct GLI1: AMPK inhibits GLI1 through β-TrCP-mediated proteasome degradation.
    Zhang R; Huang SY; Ka-Wai Li K; Li YH; Hsu WH; Zhang GJ; Chang CJ; Yang JY
    Oncotarget; 2017 Jul; 8(30):49869-49881. PubMed ID: 28562331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human RNA polymerase II-association factor 1 (hPaf1/PD2) regulates histone methylation and chromatin remodeling in pancreatic cancer.
    Dey P; Ponnusamy MP; Deb S; Batra SK
    PLoS One; 2011; 6(10):e26926. PubMed ID: 22046413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
    Pianetti S; Arsura M; Romieu-Mourez R; Coffey RJ; Sonenshein GE
    Oncogene; 2001 Mar; 20(11):1287-99. PubMed ID: 11313873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BMI1 and PTEN are key determinants of breast cancer therapy: A plausible therapeutic target in breast cancer.
    M JR; S V
    Gene; 2018 Dec; 678():302-311. PubMed ID: 30096458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural polymorphism of chromodomains in Chd1.
    Okuda M; Horikoshi M; Nishimura Y
    J Mol Biol; 2007 Jan; 365(4):1047-62. PubMed ID: 17098252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.